ANG003 Dose B

Phase 2

AAnagram Therapeutics, Inc.

ANG003 Dose B is one of 2 therapeutic programs targeting Exocrine Pancreatic Insufficiency. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Exocrine Pancreatic InsufficiencyRecruiting

Exocrine Pancreatic InsufficiencyPhase 2

Recruiting

Competition

Competitive Landscape

3 competitors in Exocrine Pancreatic Insufficiency

#DrugCompanyPhaseTrials

Creon

AbbVie

Phase 2

2 2

ANG003 Dose B

AAnagram Therapeutics, Inc.

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 2Recruiting

Exocrine Pancreatic Insufficiency

NCT07450547

Clinical

Trials by Indication[1]

Exocrine Pancreatic Insufficiency1 trial

A Phase 2, Multicenter, Randomized, Active-controlled Study to Assess the Safety and Efficacy of ANG003 at Two Different Dose Levels in Subjects With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis

Recruiting·AAnagram Therapeutics, Inc.·Phase 2·NCT07450547·113 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for ANG003 Dose B. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for ANG003 Dose B. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Anagram Therapeutics, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: AAnagram Therapeutics, Inc.

ANG003 Dose B

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Exocrine Pancreatic Insufficiency1 trial

References

Drug Info

Quick Facts

Related News